Clinical Site Services International (CSSi), the leader in global patient enrollment solutions for the clinical research industry, is pleased to announce their new partnership with TruBios.
Clinical Site Services International (CSSi), the leader in global patient enrollment solutions for the clinical research industry, is pleased to announce their new partnership with TruBios. TruBios, based out of Rockville, MD, is the only fully integrated US-based biotechnology services company focused on the Latin American region offering customized clinical research, commercialization, and venture capital solutions. TruBios is also an independent corporate partner of Johns Hopkins University MCC.
Clinical Site Services International (CSSi), a division of CSS, is partnering with TruBios to deliver CROs/Pharma and Biotech clients solutions that are focused on site performance while also allowing CSSi to expand its site network in Latin America. Pharmaceutical/CRO clients will be provided with top sites and the expertise and understanding of patients who are willing to participate in clinical research.
"Continuing to deliver the most innovative and proven enrollment solutions for our clients, whether in the US or abroad, is a challenge we embrace and one that our partnership with TruBios will address as we expand our site network in Latin America," said Chris Trizna, President of CSS. "Working together, CSSi and TruBios will be able to offer insight and knowledge to help sites in Latin America identify potential patients by utilizing enrollment strategies that are appropriate to the sites and local communities."
"Clinical Site Services and TruBios represent an impressive collaboration, as both of our companies are committed to providing innovative solutions to accelerate the development of clinical trials," said Dr. Roberto Trujillo, CEO of TruBios. "The TruBios Research Network (TRN) covers approx. 60% of the countries in Latin America and partnering with CSSi to deliver customized enrollment services will only allow both our companies to grow and expand further in those countries."
CSSi delivers high-performing, qualified sites to CRO and Pharma clients through their proprietary site management solutions. CSS has long recognized that only sites are able to enroll patients but sometimes sites are not able to identify patients from within their own databases. Understanding and recognizing this challenge by developing an individualized recruitment plan for each site, prevents delays in enrollment. By partnering with TruBios, CSSi's Latin America clients will have the ability to use qualified sites that are already identified as high performing research facilities.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.